Does Wisp Prescribe Estradiol Patches? Yes — Both Schedules, the Real Cost, and What Can Stop Treatment
Match the route to your situation
Use the free matching tool to compare patch, pill, gel, insurance, cash-pay, state, risk-history, and testing needs before paying for an online consult.
Yes. Wisp offers prescriptions for estradiol patches in weekly and twice-weekly schedules through its $99 online menopause consult. The fee includes the consult, follow-ups, and three months of care-team access; medication costs extra at your chosen pharmacy. A licensed provider decides whether a patch is appropriate, so completing intake does not guarantee a prescription.
That is the answer. Here is the part almost nobody tells you.
The $99 is not the price of the patch. The exact manufacturer, strength, National Drug Code, pharmacy price, refill count, and cost of care after the first three months are not published in advance. And because estradiol patch availability is uneven by manufacturer, strength, and NDC in 2026, the box your pharmacy can actually fill matters more than the word “patch” on Wisp’s menu.
The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.
The 30-second version
Best for you if: You want a weekly or twice-weekly estradiol patch, prefer to use your own local pharmacy, and would rather pay one consult fee than join a monthly care subscription.
Not for you if: You need the medical visit billed to insurance, want one predictable price that already includes medication, or need the same service to order and complete diagnostic testing before treatment.
| The question | The verified answer |
|---|---|
| Does Wisp prescribe estradiol patches? | Yes, if the reviewing clinician decides one is appropriate |
| Which schedules? | Weekly and twice-weekly |
| Consult price | $99 one time |
| What does $99 include? | Consult, follow-ups, and three months of care-team access |
| Is the patch included? | No. Your local pharmacy charges separately |
| Published lower-price cash benchmark | $35.82–$56.38 per 28-day box, depending on strength and schedule; not a Wisp quote |
| First-month benchmark | $134.82–$155.38 for consult plus patch, before progesterone, insurance, or a different pharmacy price |
| Where is it filled? | A local pharmacy you choose |
| Progesterone available too? | Yes. Wisp lists oral micronized progesterone and medroxyprogesterone |
| Does the menopause consult include lab testing? | No |
| How fast is the prescription sent? | Wisp says most prescriptions are sent within about three hours after intake and any required phone or video contact |
| State availability | Wisp currently says the menopause consult is available in all 50 states |
| What happens if no treatment can be prescribed? | Wisp says it charges up to $25 instead of the full consult price when no treatment can be prescribed |
| What happens after three months? | Not published. Confirm during intake |
We earn nothing from Wisp. Wisp is not an affiliate partner on this page. There is no commission link, tracking code, or financial reason for us to push you toward it.
Does Wisp prescribe estradiol patches?
Yes. Wisp’s current menopause consult page lists estradiol patches, and its July 2026 hormone-therapy guide describes both weekly and twice-weekly transdermal schedules. The prescription is not automatic: a licensed clinician reviews your intake and decides whether the medication and route fit your history.
Wisp’s menopause consult page names “estradiol patch, gel, and oral options.” Its current menopause hormone-therapy guide separately describes weekly and twice-weekly estradiol patches in strengths from 0.025 mg to 0.1 mg per day.
That resolves the main question. It does not tell you which box you will receive.
Provider-stated versus independently checked
| Claim | What Wisp publishes | What we verified on August 12, 2026 | What it means before you pay |
|---|---|---|---|
| Estradiol patches are offered | Patch listed on the consult page | Confirmed on Wisp’s current consult page and July 2026 guide | The route is genuinely on the menu |
| Both schedules are available | Weekly and twice-weekly patch language | Confirmed in Wisp’s current guide and treatment materials | You can state a schedule preference, but the prescriber decides |
| The consultation costs $99 | $99 | Confirmed | Medication is still separate |
| Care lasts three months | Consult, follow-ups, and three-month care-team access | Confirmed | Ask what continued care costs before the window closes |
| Medication goes to a local pharmacy | Same-day local-pharmacy sending if prescribed | Confirmed | Insurance or a discount card may apply to the medication even though the consult is cash-pay |
| Service is nationwide | Available in all 50 states | Confirmed as Wisp’s current published policy | Recheck the live eligibility screen before submitting payment |
| Exact patch is disclosed before intake | No public brand, manufacturer, NDC, or guaranteed strength | Not found on Wisp’s public consult page | The pharmacy label is where you learn the exact product |
| Ongoing-care price is disclosed | No public continuation price after three months | Not found | Ask during intake and save the answer in your portal |
“Available” is not the same as “guaranteed”
Wisp’s own legal footer says it helps arrange a visit with an independent physician who evaluates whether you are an appropriate candidate and, when appropriate, may write a prescription that you can fill at a pharmacy you choose.
Three parts of that sentence matter.
Wisp is the platform, not the prescription decision. The clinician decides.
“May write” means may write. Completing the intake is not an order for a patch.
Your pharmacy is your choice. That is one of Wisp’s strongest practical advantages when a particular manufacturer is unavailable.
If this model fits what you are looking for
You are paying $99 for a clinical decision, follow-up access, and the ability to use your own pharmacy—not for a guaranteed prescription or an all-in medication package.
See the current menopause consult and check eligibility on Wisp
Medication costs extra · Prescription not guaranteed · No commission to us
The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.
What does Wisp’s $99 menopause consult include?
The $99 covers the online consultation, follow-ups, and three months of access to Wisp’s care team. It does not include the estradiol patch, progesterone, pharmacy copays, or testing. If no treatment can be prescribed, Wisp says it charges up to $25 rather than the full consult price.
Wisp puts the core price sentence directly on its menopause consult page: the consult, follow-ups, and three-month care-team window are included; medication is paid for at the local pharmacy.
| Included in the $99 | Not included in the $99 |
|---|---|
| Online medical intake and clinical review | The estradiol patch |
| Follow-up access during the three-month window | Progesterone or another prescribed medication |
| Care-team messaging | Pharmacy copay or cash price |
| Prescription sent to your chosen pharmacy, if appropriate | Diagnostic workup or clinician-ordered testing outside Wisp |
| Treatment adjustments during the included care window | A guaranteed manufacturer, brand, strength, or pickup time |
| Up to a $25 review charge instead of the full fee when no treatment can be prescribed, according to Wisp’s general pricing page | Published continuation pricing after three months |
It is a one-time consult, not a monthly Wisp menopause subscription
That is unusual enough to say plainly. The page lists one $99 fee rather than a recurring monthly menopause membership.
Wisp also displays FSA/HSA acceptance on the consult page. Eligibility for reimbursement still depends on your plan’s rules and documentation requirements.
The membership discount does not rescue the menopause price
Wisp+ advertises discounts on much of the site. Its own membership terms exclude menopause and weight-care consults and products.
So the damaging admission stays simple: do not join Wisp+ expecting it to reduce this $99 menopause consult. It does not.
The site also displays a WELCOME15 promotion. We could not verify from Wisp’s published terms that the code applies to the menopause consult. Treat it as confirm at checkout, not a promised discount.
How much does an estradiol patch cost through Wisp?
Wisp charges $99 for care and sends the prescription to your pharmacy. Current published lower-price cash benchmarks for generic estradiol patches run from $35.82 to $56.38 for a 28-day box across the strengths and schedules captured below. Your real price can be lower with insurance or higher at a different pharmacy.
Here is the equation without the affiliate math people usually hide:
First-month cost = $99 Wisp consult + pharmacy price for the patch + pharmacy price for progesterone if prescribed
Using the published lower-price figures below, the consult plus patch comes to $134.82–$155.38 before progesterone. That is a benchmark, not a quote. It does not predict your copay or guarantee that the lowest-priced pharmacy has the product in stock.
Current published cash benchmarks by schedule and strength
Source: Drugs.com estradiol patch price guide, captured August 12, 2026. These are published “from” prices for cash-paying customers, not Wisp prices and not guaranteed pharmacy quotes.
| Strength delivered per day | Twice-weekly: 8 patches | Weekly: 4 patches | Weekly price difference at the same strength |
|---|---|---|---|
| 0.025 mg | $35.83 | $54.57 | +$18.74 (52.3%) |
| 0.0375 mg | $35.82 | $56.36 | +$20.54 (57.3%) |
| 0.05 mg | $44.15 | $56.38 | +$12.23 (27.7%) |
| 0.06 mg | Not listed | $48.41 | No matched comparison |
| 0.075 mg | $43.50 | $54.43 | +$10.93 (25.1%) |
| 0.1 mg | $53.05 | $53.37 | +$0.32 (0.6%) |
Weekly is not automatically 28% to 57% more
That was true for three of the lower and middle matched strengths in the earlier draft. It is not true across the full current table.
At 0.025 mg and 0.0375 mg, the published weekly benchmark is more than 50% higher. At 0.075 mg it is about 25% higher. At 0.1 mg, the two schedules are almost the same price.
So the clean rule is: compare the same strength, pharmacy, manufacturer, and discount method before deciding that one schedule costs more.
Insurance, HSA, FSA, and coupons are four different questions
- The $99 visit and the pharmacy medication are separate bills.
- Wisp does not publish medical-insurance billing for the menopause consult. Treat the visit as cash-pay unless checkout says otherwise.
- Your pharmacy benefit may cover the patch. Wisp says eligible insurance can be applied to pharmacy pickup costs.
- Wisp displays FSA/HSA acceptance. Your plan administrator decides whether a particular expense qualifies.
- A discount card is not insurance. Wisp links to its own GoodRx discount card for cash pharmacy purchases.
If the unbundled price works for you
The model is straightforward: one $99 care fee, then whatever your own insurance, pharmacy, or discount card does with the prescription price.
Check the current Wisp consult details before paying
Confirm the final fee at checkout · Medication is separate · No commission to us
Which estradiol patch will Wisp actually prescribe?
Wisp does not publicly guarantee a brand, manufacturer, NDC, or strength before clinical review. It publishes the route and both schedules. The prescriber selects the medication, and the pharmacy dispenses the available product that matches the prescription and substitution rules.
This is the honest gap in Wisp’s public information.
An NDC, or National Drug Code, identifies a particular marketed drug product and package. Two boxes can both say “estradiol transdermal system 0.05 mg/day” and still come from different manufacturers, use different adhesives, carry different patch sizes, and have different local availability.
FDA approval belongs to the specific drug product—not the telehealth platform. Wisp is not “FDA-approved,” and no telehealth company is. To identify the product you actually received, use the pharmacy label and box.
The five things to record from your pharmacy label
- Drug name — usually “estradiol transdermal system”
- Manufacturer — the company that made the dispensed product
- NDC — the exact product and package identifier
- Strength — stated as milligrams delivered per day
- Directions — weekly or twice-weekly, exactly as written on your prescription label
Do not infer the schedule from patch count alone. Four patches often represent a four-week weekly supply and eight often represent a four-week twice-weekly supply, but the pharmacy directions are the controlling instruction.
Save a photo of the front label and the NDC. When a refill is unavailable, those two details let the pharmacist and prescriber identify whether the problem is your exact product or the entire route.
Can you get an estradiol patch filled in 2026?
Not every product is consistently available, but the shortage is not universal. ASHP’s August 7, 2026 bulletin lists affected weekly and twice-weekly products while also naming available alternatives in both schedules. Availability depends on the manufacturer, strength, NDC, wholesaler, and your pharmacy’s local inventory.
That distinction matters. “Estradiol patches are out” is too broad. “This manufacturer’s 0.0375 mg weekly NDC is back ordered” is a problem a pharmacist and prescriber can work with.
Current product-level supply picture
Source: ASHP Drug Shortage Bulletin: Estradiol Transdermal System, updated August 7, 2026. Local pharmacy inventory can differ from national manufacturer status.
| Product or manufacturer | Schedule | ASHP status on August 7, 2026 |
|---|---|---|
| Sandoz estradiol patches | Weekly | All listed strengths affected; 0.0375 mg and 0.1 mg on back order, other presentations on allocation |
| Climara from Bayer | Weekly | Listed as available |
| Viatris/Mylan weekly products | Weekly | Listed among available products |
| Dotti from Amneal, 0.0375 mg and 0.1 mg | Twice-weekly | On back order with no estimated release date |
| Dotti 0.025 mg, 0.05 mg, and 0.075 mg | Twice-weekly | Listed among available products |
| Lyllana from Amneal | Twice-weekly | Listed as available |
| Noven/Grove products | Twice-weekly | All presentations on intermittent back order with weekly releases |
| Zydus 0.05 mg, 0.075 mg, and 0.1 mg | Twice-weekly | On allocation |
| Viatris/Mylan 0.05 mg, NDC 00378-4642-26 | Twice-weekly | Intermittent back order; supplies released as available |
| Other listed Viatris/Mylan twice-weekly NDCs | Twice-weekly | Listed among available products |
What the table actually proves
Both schedules have affected products. Both schedules also have available products.
So “switch to weekly” is not a universal shortage solution. Neither is “stay twice-weekly.” The useful question is which product at your prescribed strength can your pharmacy obtain now?
What to say at the pharmacy
“Which manufacturer and NDC of my prescribed estradiol patch strength can you fill or order? If that product is unavailable, which available alternative should my prescriber send?”
That question gives the prescriber something specific to act on. Do not ask the pharmacist to change your strength or schedule without a new prescription when one is required.
Why Wisp’s unbundled model can help here
This is where the same flaw that makes Wisp less predictable can become useful.
Wisp does not bundle a specific patch into the $99 price. That means you are not tied to one mail-order inventory stream. You can use a local pharmacy, ask about another manufacturer or schedule, and message the Wisp care team during the included three-month window if a new prescription is needed.
Wisp also lists estradiol gel and oral options. A route change is a clinical decision, not a pharmacy substitution, but the menu gives the clinician more than one path when a particular patch cannot be filled.
If pharmacy flexibility is the reason Wisp fits
One consultation, your own pharmacy, both patch schedules, and follow-up access during a period of manufacturer-specific shortages—that is the strongest case for this model in 2026.
Check current eligibility for Wisp’s menopause consult
Supply is not guaranteed · Any medication change requires the prescriber · No commission to us
Does Wisp prescribe progesterone with an estradiol patch?
Wisp lists oral micronized progesterone and medroxyprogesterone as menopause options. Its patch treatment materials tell patients with a uterus to take prescribed progesterone with the patch. The exact progestogen, dose, and schedule remain clinical decisions based on the patient’s history and estrogen regimen.
Wisp’s patch guide says:
“If you have a uterus, it’s important to take your progesterone along with your patch for your safety.”
That matches the current FDA labeling principle. A current estradiol patch label on DailyMed says clinicians should generally consider adding a progestogen when systemic estrogen is prescribed to a postmenopausal woman with a uterus, because progestogen lowers the risk of endometrial hyperplasia and endometrial cancer from unopposed estrogen.
A woman without a uterus generally does not need a progestogen with systemic estrogen, although the label identifies exceptions such as some patients with residual endometriosis. Your clinician makes that call from your actual surgical and medical history.
What Wisp currently offers—and what it does not
| Option | Current Wisp position |
|---|---|
| Oral micronized progesterone | Listed as available |
| Medroxyprogesterone, generic Provera | Listed as available |
| Estradiol/norethindrone acetate combination | Wisp’s July 2026 guide says it does not offer it |
| Bijuva or generic estradiol plus micronized progesterone in one capsule | Wisp’s July 2026 guide says it does not offer it |
The one-pill combination claim in the earlier draft was wrong. Wisp discusses those products for education, then explicitly says it does not offer them.
Three questions to ask during intake
- “I have a uterus. What is the plan for protecting my uterine lining with systemic estrogen?”
- “Which progestogen and schedule are you considering, and why?”
- “What bleeding pattern should make me contact you or seek an in-person evaluation?”
Low-dose vaginal estrogen is a different clinical question from systemic estradiol patches. See Do You Need Progesterone With Vaginal Estrogen? for that route-specific answer.
Who may not be eligible for a Wisp estradiol patch?
Wisp’s patch treatment guides contain a 17-item stop-and-contact list. That list is broader than the formal contraindications in a current FDA-approved estradiol patch label. Some entries are label contraindications; others are risk factors, unresolved findings, or telehealth caution flags that may require more history, testing, or in-person care.
The HRT Index captured and compared Wisp’s weekly and twice-weekly patch treatment guides on August 12, 2026. The guides listed:
Pregnancy · breastfeeding · abnormal vaginal bleeding · history of a blood clot · blood-clotting disorder · history of breast, ovarian, uterine, or endometrial cancers · history of a heart attack · cardiac disease · history of stroke or TIA · abnormal or concerning mammogram results · gallbladder disease · lupus · limited mobility · metastatic melanoma · liver disease, excluding nonalcoholic fatty liver disease in Wisp’s wording · type 1 diabetes · uncontrolled high blood pressure
That is Wisp’s clinical-policy list. It is not the same thing as the FDA label’s contraindications section.
Wisp’s list versus the current estradiol patch label
| Wisp-listed issue | Current FDA label category | Practical reading |
|---|---|---|
| Undiagnosed abnormal genital bleeding | Contraindication | Needs evaluation before systemic estrogen |
| Breast cancer or history of breast cancer | Contraindication | Online intake should not override this label restriction |
| Estrogen-dependent neoplasia | Contraindication | Requires specialist-level clinical judgment |
| Active or prior DVT/PE | Contraindication | Formal label stop |
| Active or prior stroke or myocardial infarction | Contraindication | Formal label stop |
| Known thrombophilia | Contraindication | Formal label stop |
| Hepatic impairment or disease | Contraindication | Formal label stop |
| Serious hypersensitivity to the patch product | Contraindication | Includes product-specific allergy concerns |
| Gallbladder disease | Warning/precaution, not listed as a contraindication | Still relevant because estrogen can increase gallbladder risk |
| Lupus, diabetes, hypertension, cardiac risk, or limited mobility | Risk factor or precaution rather than a blanket contraindication in this label | May change route choice, workup, or whether telehealth is the right starting point |
| Abnormal or concerning mammogram | Not named as a standalone contraindication in this label | An unresolved finding needs follow-up before routine online prescribing |
| Ovarian cancer history or metastatic melanoma | Not named as standalone contraindications in this specific patch label | Wisp applies a broader policy; disclose the history and expect clinician review or deferral |
Do not read the right-hand column as permission to leave something off the intake. Wisp’s list controls what its service asks you to stop and report. The FDA label controls the drug product. Your actual clinical history controls what happens next.
Two details worth raising before you pay
Adhesive reactions: Wisp’s patch materials flag adhesive allergy. If medical tape or bandages have caused a significant reaction, say that before choosing the route.
Medication and supplement review: Wisp’s guides flag additional hormone therapy, lamotrigine, St. John’s wort, DIM supplements, and thyroid medication. Do not stop any prescribed medication on your own. Put every prescription, over-the-counter drug, and supplement into the intake so the clinician can review the combination.
There is no sales button in this section. An eligibility and contraindication list is not a place to push a consult.
Does Wisp require blood tests or a video visit?
Wisp says its menopause providers can review history and recommend screening, but the menopause service does not order or perform the tests that may be needed before treatment. If testing is required, Wisp directs the patient to an in-person healthcare provider. The process begins online, with phone or video contact when necessary.
Wisp states this directly in its HRT eligibility guide:
“Wisp does not order or perform the above tests. If testing is needed, it must be ordered and completed through your in-person healthcare provider before treatment can begin.”
Wisp’s general Terms discuss separate laboratory products that the platform may facilitate. That does not change the menopause-consult policy above: the consult does not promise an integrated diagnostic workup ordered and managed by the same menopause clinician.
Routine hormone levels are not the same as necessary diagnostic testing
A current FDA-approved estradiol patch label says serum FSH and estradiol levels have not been shown useful for managing postmenopausal women treated for moderate-to-severe vasomotor symptoms or vulvar and vaginal atrophy.
That does not mean “labs never matter.” It means a routine hormone number is not the universal gate or dosing target for ordinary postmenopausal symptom treatment.
Testing or in-person evaluation can still matter when the history raises another question—unexplained bleeding, an unresolved breast finding, thyroid symptoms, suspected premature ovarian insufficiency, pregnancy possibility, or another condition that changes the diagnosis or safety plan.
Do not assume the process will be message-only
Wisp says most prescriptions are sent within about three hours after the medical intake form and a phone call or video chat when necessary. That is a company timing claim about prescription sending, not a guaranteed pickup time.
If a synchronous call would be impossible for you, ask before submitting payment. Wisp does not promise that every menopause case can be completed asynchronously.
When testing or an in-person evaluation should come first
Do not force an online pathway to fit a situation it cannot safely complete. Use Find My HRT Path to identify a provider model that can handle your testing, insurance, route preference, and risk history—and to flag when in-person care is the better first step.
What happens after Wisp’s first three months of care?
Wisp publishes what the initial $99 covers but does not publish the price of continued menopause care after the three-month access window. It also does not state on the public consult page how many refills the initial prescription will authorize. Ask both questions during intake and save the answer.
We could not verify a public continuation fee on August 12, 2026.
Ask:
- “How many refills will the initial prescription authorize?”
- “What will continued clinical access cost after the first three months?”
- “Will I need a new paid review before the next refill cycle?”
- “What happens if a pharmacy shortage requires a prescription change after the included window ends?”
Get the response in your portal rather than relying on memory.
What the refund language actually says
Wisp’s How It Works page says that when a patient cannot be prescribed any treatment, the company charges up to $25 instead of the full consult price to cover the provider review.
Wisp’s Terms of Service, last updated May 6, 2026, separately say product sales are final except for narrow situations such as an item being out of stock, a prescription product being unavailable at local pharmacies, damage, or nonreceipt. The Terms also say other fees are nonrefundable unless Wisp specifies otherwise or the law requires it.
The practical point is not complicated: the fee pays for clinical review. Do not assume you can obtain a full refund simply because you decide not to fill or use a prescription after that review.
What is the one thing to know before paying Wisp?
Here it is, straight.
Wisp does not put the medication inside the $99 price, and its menopause consult does not order the testing you may need. If your priority is one predictable all-in payment, medical-insurance billing for the visit, or a clinician who orders and follows the diagnostic workup inside one program, Wisp is not the cleanest fit.
That is not a small footnote. It is the reason some women should choose a different care model.
But the same unbundled structure creates Wisp’s best advantage. You keep control of the pharmacy. Your insurance or a discount card may reduce the drug price. And when one manufacturer’s patch is unavailable, you are not trapped inside a single subscription pharmacy’s inventory. During the included care window, the prescriber can evaluate a different manufacturer, schedule, or route.
Bundled care is simpler—until the product inside the bundle is the product nobody can ship.
That is the trade. Pick the side that matches your life.
Not sure which side fits? Use Find My HRT Path before paying. It matches the care model to your symptoms, uterus status, preferred route, insurance or cash-pay situation, state, and risk history instead of forcing every woman into the same answer.
How do Wisp’s patch warnings compare with the current FDA label?
FDA began changing menopausal hormone-therapy boxed warnings in November 2025, but the rollout is product-specific. The first six revised labels were approved in February 2026, and FDA’s current updated-product list does not include an estradiol patch. A once-weekly estradiol patch label revised in June 2026 still carries the older boxed-warning language.
That corrects the easy but inaccurate version of this story.
The timeline
- November 10, 2025: FDA announced that it was working with manufacturers to remove boxed-warning references to cardiovascular disease, breast cancer, and probable dementia from menopausal hormone-therapy products. FDA said it was not seeking to remove the endometrial-cancer warning from systemic estrogen-alone products.
- February 12, 2026: FDA approved the first six revised labels.
- Current FDA updated-product list: Prometrium, Divigel, Cenestin, Enjuvia, Estring, and Bijuva. No estradiol patch appears on that list as of this verification.
- Current patch label check: A DailyMed label for a once-weekly estradiol transdermal system revised June 2026 still includes cardiovascular, breast-cancer, and probable-dementia language in its boxed warning.
So Wisp’s patch treatment materials cannot simply be declared “behind the FDA” as though every patch label has already changed. The policy changed first; individual product labels are changing one by one.
The label on the box your pharmacy dispenses remains the product-specific authority. Read that label, not a generic HRT summary—including ours—when you need the warnings for your exact NDC.
The endometrial-cancer point remains central for systemic estrogen used without a progestogen in a woman with a uterus. That is why the progesterone plan belongs near the top of this decision, not buried in fine print.
What did The HRT Index actually verify?
We checked Wisp’s current menopause price, medication menu, state claim, local-pharmacy policy, care window, Wisp+ exclusion, general no-treatment review fee, terms, lab policy, and July 2026 HRT guide on August 12, 2026. We also compared live cash-price data, current ASHP supply data, FDA actions, and a current DailyMed patch label.
Verified directly on August 12, 2026
- Wisp’s $99 menopause consult price
- Consult, follow-ups, and three months of care-team access
- Medication charged separately at a local pharmacy
- Estradiol patch, gel, and oral options on the current consult page
- Weekly and twice-weekly patch schedules in Wisp’s current guide
- Oral micronized progesterone and medroxyprogesterone options
- Wisp’s statement that it does not offer estradiol/norethindrone acetate, Bijuva, or generic estradiol plus micronized progesterone as a combination capsule
- Wisp’s current all-50-states claim
- Pharmacy-of-choice language and the “most prescriptions within about three hours” company claim
- Wisp+ exclusion for menopause consults and products
- The “up to $25” review charge when no treatment can be prescribed, as stated on Wisp’s general pricing page
- Wisp’s menopause testing policy
- Published 28-day cash-price benchmarks by schedule and strength
- ASHP’s product- and NDC-level shortage status, updated August 7, 2026
- Current FDA/DailyMed contraindication and labeling language
Verified from The HRT Index’s direct treatment-guide capture
- Separate weekly and twice-weekly Wisp patch treatment guides
- The guide instruction for progesterone when a patient has a uterus
- The 17-item stop-and-contact list
- Adhesive-allergy language
- The guide’s medication and supplement flags
Not publicly resolved
- The exact patch brand, manufacturer, NDC, and strength a particular patient will receive
- Whether WELCOME15 applies to the menopause consult
- How many refills the initial prescription will include
- What continued clinical access costs after three months
- A customer review that can be verified as specifically describing a Wisp estradiol patch prescription
We publish the unresolved list because a page that claims to know a private prescribing decision before intake should make you suspicious.
How this page was reviewed
This page was produced under The HRT Index Verification Standard. We read published prices, separate FDA-approved and compounded medications, verify state availability and insurance language, distinguish provider claims from independent checks, and recheck time-sensitive facts on a fixed schedule.
We evaluate providers on five pillars, always in this order: clinical legitimacy, care quality, medication fit, price transparency, access. We do not turn those into a made-up numeric provider score.
What Wisp’s wording means in practice
| Wisp wording | Practical meaning |
|---|---|
| “Suite of prescription options” | A clinician’s menu, not a catalog the patient can order from |
| “Available in all 50 states” | Wisp’s current service-availability claim; individual prescribing still depends on clinician and state requirements |
| “$99 includes consult, follow-ups, and 3-month access” | Clinical care is included; medication is not |
| “Same-day local pharmacy” | The prescription may be sent the same day; stock, insurance processing, and pickup time are separate |
| “Bioidentical” | A description of molecular structure, not an FDA approval category and not a synonym for compounded |
| “May write a prescription” | Intake does not guarantee treatment |
Are there verified customer reviews specifically about Wisp estradiol patches?
We could not verify an attributable customer review that clearly documents a Wisp estradiol patch prescription, so we are not publishing a patch testimonial. Wisp’s consult page displays a 4.3-out-of-5 company-review snapshot, but that is a company-wide rating—not evidence about patch prescribing, effectiveness, or safety.
Several review pages blend general Wisp customer comments with menopause claims. That is not good enough for this page.
A review about UTI shipping does not prove what happens during a menopause intake. A general Trustpilot score does not prove that a patch was prescribed. And no customer testimonial can establish medical effectiveness or safety for someone else.
So there is no glowing quote here. That absence is deliberate.
Is Wisp the right fit for you?
Wisp is a strong fit when the goal is a weekly or twice-weekly estradiol patch prescribed online, filled at a pharmacy you choose, without a recurring menopause subscription. It is a weaker fit when you need insurance billing for the visit, integrated testing, or a single price that already contains the medication.
| If this is your situation | Best starting point | Why |
|---|---|---|
| You want a patch, your own pharmacy, and no monthly care subscription | Wisp may fit | $99 care fee, both schedules, three-month adjustment window |
| You need the medical visit billed to insurance | An insurance-billing menopause provider | Wisp does not publish insurance billing for the $99 consult |
| You need the same clinician to order and manage diagnostic testing | A lab-capable or in-person service | Wisp directs required testing to an in-person provider |
| You want medication included in one predictable program price | A bundled medication program | Wisp’s pharmacy charge is separate and variable |
| You have postmenopausal bleeding, an unresolved abnormal mammogram, or another issue needing evaluation | In-person care first | The priority is evaluation, not accelerating an online prescription |
| You are unsure which route or provider model fits | Find My HRT Path | It sorts by symptoms, uterus status, route, risk, insurance, cash-pay needs, and state |
Why this page does not substitute a compounded provider for the patch you searched for
An FDA-approved brand or generic estradiol patch and a compounded hormone preparation are different regulatory categories.
FDA-approved drug products are reviewed for safety, effectiveness, quality, labeling, and manufacturing. Compounded drugs are not FDA-approved, and FDA does not review them for those same determinations before marketing. Compounding can serve a legitimate patient-specific need when an FDA-approved product cannot meet it, but it should not be presented as interchangeable with, safer than, or more natural than an FDA-approved patch.
This page is about pharmacy-dispensed estradiol transdermal systems. It does not move a reader into a compounded lane simply because a compounded provider is an affiliate.
Where to go from here
Wisp’s model fits: Check current menopause-consult eligibility on Wisp — no commission to us
Your situation still depends on testing, insurance, route, or risk history: Use Find My HRT Path before paying anyone.
Frequently asked questions
Does Wisp prescribe estrogen patches?
Yes. Wisp’s current menopause materials list estradiol patches in weekly and twice-weekly schedules. A licensed clinician must decide that the medication is appropriate; intake does not guarantee a prescription.
Is the estradiol patch included in Wisp’s $99?
No. The $99 covers the consult, follow-ups, and three months of care-team access. Your local pharmacy charges separately for the patch and any progesterone prescribed with it.
Is the $99 charged every month?
Wisp presents the menopause consult as a one-time $99 fee with a three-month care window, not a monthly menopause subscription. Continued-care pricing after three months is not published on the consult page.
What happens if Wisp cannot prescribe treatment?
Wisp’s general How It Works page says that when no treatment can be prescribed, it charges up to $25 instead of the full consultation price to cover the provider review. Confirm how that policy applies to your menopause intake before checkout.
Can I request a weekly or twice-weekly patch?
Yes, you can state a preference because Wisp discusses both schedules. The clinician decides what to prescribe, and local product availability can affect which prescription is practical to fill.
Can I use insurance for Wisp’s estradiol patch?
Treat the $99 consultation as cash-pay unless checkout states otherwise. Your pharmacy insurance benefit may still cover the prescribed patch because the medication charge is separate from the Wisp consult.
Does Wisp accept HSA or FSA funds?
Wisp displays FSA/HSA acceptance on the menopause consult page. Your plan administrator controls eligibility and may require documentation.
Does Wisp require blood tests?
The menopause service does not promise routine lab testing. Wisp says its providers can recommend screenings, but required testing must be ordered and completed through an in-person healthcare provider before treatment begins.
Is Wisp’s estradiol patch FDA-approved?
FDA approval applies to a specific drug product, not to Wisp. Check the manufacturer and NDC on the box or pharmacy label to identify the exact product you received and confirm its approval status in FDA or DailyMed records.
Does Wisp prescribe compounded hormones for menopause?
Wisp’s public menopause material uses the word “bioidentical,” but that word does not tell you whether a drug is FDA-approved or compounded. For the patch on this page, verify the dispensed manufacturer and NDC. Never treat “bioidentical” as a synonym for compounded or as a safety claim.
Does Wisp prescribe progesterone with an estradiol patch?
Wisp lists oral micronized progesterone and medroxyprogesterone. Its patch treatment materials instruct a patient with a uterus to take prescribed progesterone with the patch; the clinician determines the product and schedule.
Can Wisp send the prescription to my own pharmacy?
Yes. Wisp says an appropriate prescription can be filled at the pharmacy of your choice. Wisp’s same-day or three-hour language refers to sending the prescription, not guaranteed same-day pickup.
What if my pharmacy cannot get the prescribed patch?
Ask which manufacturer and NDC of your prescribed strength the pharmacy can obtain, then send that information to the prescriber. Any change in manufacturer restrictions, schedule, strength, or route must follow the prescription and clinician’s directions.
Does Wisp prescribe testosterone for women?
Testosterone does not appear on Wisp’s published menopause consult menu. Testosterone is also a Schedule III controlled substance in the United States, so any legitimate prescription requires controlled-substance compliance and clinician oversight; it is not interchangeable with ordering estrogen or progesterone online.
The bottom line
Yes—Wisp prescribes estradiol patches in weekly and twice-weekly schedules through a $99 online menopause consult. The $99 pays for the clinical review, follow-ups, and three months of care-team access. It does not buy the patch, guarantee a prescription, guarantee a manufacturer, or settle what continued care will cost after three months.
The published lower-price pharmacy benchmark we captured was $35.82–$56.38 for a 28-day box, putting the consult plus patch at $134.82–$155.38 before progesterone. Your actual pharmacy price can be different. In 2026, supply is product-specific: some weekly and twice-weekly products are affected, and others remain available.
If you have been circling this decision for weeks, waiting for someone to tell you it is reasonable to ask: it is reasonable to ask. Estradiol patches are an established prescription treatment for menopausal symptoms, and wanting a clinician who will discuss the route with you is not asking for too much.
Just carry three facts into checkout.
The $99 buys a clinical decision, not a guaranteed prescription.
Your pharmacy price and exact product come later.
Bleeding, unresolved imaging, clot history, cancer history, liver disease, or another risk flag belongs in the open—not buried to get through an intake.
Then choose the care model that can actually handle your situation.
Still not sure which HRT program is right for you? Use our free matching tool. → Find My HRT Path
The tool is designed to flag when online care is not the right starting point. Review our consumer health data privacy policy before entering sensitive information.
This article is educational research, not medical advice and not a substitute for care from a qualified clinician. It was not medically reviewed by a clinician. FDA-approved and compounded medications are separate regulatory categories throughout this page. We may earn commissions from some provider links elsewhere on The HRT Index; Wisp is not an affiliate partner on this page. Last verified August 2026. How we verify · Affiliate disclosure · Corrections
Sources
- Wisp Menopause Consult, accessed August 12, 2026
- Wisp: How It Works, accessed August 12, 2026
- Wisp: A Guide to Hormone Replacement Therapy for Menopause, dated July 13, 2026 and accessed August 12, 2026
- Wisp: Is HRT Right for Me?, accessed August 12, 2026
- Wisp+ Membership Terms, accessed August 12, 2026
- Wisp Terms of Service, last updated May 6, 2026
- Drugs.com Estradiol Patch Price Guide, captured August 12, 2026
- ASHP Drug Shortage Bulletin: Estradiol Transdermal System, updated August 7, 2026
- DailyMed: Estradiol Transdermal System, Once Weekly, label revised June 2026
- FDA: HHS Advances Women’s Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy, November 10, 2025
- FDA: FDA Approves Labeling Changes to Menopausal Hormone Therapy Products, February 12, 2026
- FDA: Menopausal Hormone Therapies With Updated Prescribing Information, accessed August 12, 2026
- FDA: What Telehealth Companies Should Know When Promoting Compounded Drugs, June 2026
- The Menopause Society: Hormone Therapy, accessed August 12, 2026
- DEA Drug Scheduling, accessed August 12, 2026